Skip to content
value.today

Exicure, Inc. vs Pharmicell Co., Ltd.

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Pharmicell Co., Ltd. is the larger company by market value: $514 M against $6 M for Exicure, Inc., 87 times as much (market caps of Oct 30, 2026 for Exicure, Inc. and Aug 1, 2026 for Pharmicell Co., Ltd.). Pharmicell Co., Ltd.'s value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

036721081432020202120222023202420252026Exicure, Inc. 3Pharmicell Co., Ltd. 115

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$0B$0B$0B$0B20172018201920202021202220232024Exicure, Inc. $0B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureExicure, Inc.
XCUR · #26,753 in the world
Pharmicell Co., Ltd.
005690.KS · #12,422 in the world
Profile
Country🇺🇸 USA🇰🇷 South Korea
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
Founded2011—
Size
Market cap$6 M$514 M
Net income$-5 M—
Valuation
Price to book1.5×—
Free cash flow yield-144.3%—
Profitability
Return on equity-92.5%—
Altman Z-score zone——
Data as ofMarket cap Oct 2026; ratios FY2025Market cap Aug 2026

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Exicure, Inc. or Pharmicell Co., Ltd.?

Pharmicell Co., Ltd. is the larger company by market value: $514 M against $6 M for Exicure, Inc., 87 times as much (market caps of Oct 30, 2026 for Exicure, Inc. and Aug 1, 2026 for Pharmicell Co., Ltd.). Pharmicell Co., Ltd.'s value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.

Sources#

Every figure on this page comes from these, with the date shown next to it.